# Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

> **NCT00703638** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 16 (actual)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Mesothelioma
- Pancreatic Cancer
- Prostate Cancer
- Sarcoma

## Interventions

- **DRUG:** cisplatin
- **DRUG:** pemetrexed disodium
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00703638
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-09
- **Final completion:** 2010-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703638, "Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00703638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*